Back to Search

A Phase 1b/2 Study of Agents Targeting the Mitogen-Activated Protein Kinase Pathway in Patients With Advanced Gastrointestinal Malignancies (HERKULES-3)

  • Protocol Number: 202109114
  • Principal Investigator: Grierson, Patrick
  • Cancer Types: Gastrointestinal

Learn more about this study at: clinicaltrials.gov

For more information on this trial, contact us here:

Phone
800-600-3606
Email
info@ccadmin.wustl.edu

Brief Summary

To evaluate the safety and tolerability of escalating doses of ERAS-007 in combination with other cancer therapies in study participants with advanced GI malignancies.
To determine the Maximum Tolerated Dose (MTD) and/or Recommended Dose (RD) of ERAS-007 administered in combination with other cancer therapies.
To evaluate the antitumor activity of ERAS-007 in combination with other cancer therapies.
To evaluate the PK profiles of ERAS-007 and other cancer therapies when administered in combination.

Protocol Interventions

ERAS-007, Encorafenib, Cetuximab, Palbociclib